Suzanne Lepage

Bridging the group benefits and pharmaceutical industries

[Suzanne Lepage @SuzanneLepage]

How plan sponsors, insurers are considering coverage of weight-loss drugs amid rising use of Ozempic via @BenCanMag https://t.co/bbjZuvgFJO

[Suzanne Lepage @SuzanneLepage]

At @BenCanMag Canadian Leadership Council on Drug Plan Partnerships we brought together plan advisors to discuss innovation in drug development and its impact on Canadian private drug plans. Would love to hear your thoughts.
https://t.co/YYjC8wJqeg

[Suzanne Lepage @SuzanneLepage]

The Plan Sponsor's Guide to Rare Diseases addresses many of the issues that impact Canadian private plans. I learned a lot by working on this and hope you do too. https://t.co/GH3C562VN1 via @BenCanMag #RareDisease #benefits

[Suzanne Lepage @SuzanneLepage]

Honoured to author the private payer section of @IQVIA Canada PharmaFocus report again this year. (Subscription Required)

[Express Scripts CA @ExpressRxCanada]

At Express Scripts Canada, we're tracking medications and technologies that improves the health of Canadians. If you'd like an in-depth view, download your copy of our 2022 Drug Trend Report here: https://t.co/v6Q2Pr3qtE

#HR #PBM #Benefits #TPA

[Suzanne Lepage @SuzanneLepage]

Catch up on @BenCanMag Chronic Disease at Work conference coverage https://t.co/hciTMFRNt3

[Suzanne Lepage @SuzanneLepage]

Catch up on the coverage from @BenCanMag 2021 Face to Face in Drug Plan Management Forum
https://t.co/Ix5quyiqyg

[Suzanne Lepage @SuzanneLepage]

Gene therapies could reshape the way genetic diseases are managed because they target the underlying cause of genetic disease rather than just treating complex medical conditions. I learned a lot writing this for @BenCanMag and I hope you do to. https://t.co/5kxCUpWDco

[Suzanne Lepage @SuzanneLepage]

My article in the November 2021 issue of IQVIA PRA includes profiles of several Canadian private payers to help PRA subscribers improve partnerships, submissions and ongoing collaborations. @IQVIA

[Suzanne Lepage @SuzanneLepage]

PGx testing may be included in employee benefits plans; however, there is significant variability between providers and tests. This guide gives practical guidance on selecting a provider. I learned a lot working on this project, and I hope you do too.

https://t.co/8XVr1lRYxZ

[Suzanne Lepage @SuzanneLepage]

The PLAN SPONSORS GUIDE TO DIABETES provides education and resources on how to support plan members living with diabetes or caregivers of people with diabetes. I learned so much writing this guide, and I hope you do too!

https://t.co/Bs6pijvdAk

[MORSE Consulting Inc @MorseConsult]

@SuzanneLepage & Lindy Forte provide thoughtful insight into the importance of transparency in the Private Payer's HTA process at today's #CADTHSymp breakfast session.

[Suzanne Lepage @SuzanneLepage]

.@IQVIA Canada PRA Subscribers check out the August 2021 issue for my article on @GSC_1957 Green Shield Canada's Biosimilar Transition Program.

[Suzanne Lepage @SuzanneLepage]

.@BenCanMag 2021 CLC on Drug Plan Partnerships examined the evolution of health economics & formulary decision-making in Canadian private drug plans. Managed formularies help manage drug plan costs, but also present potential financial & legal risks https://t.co/RJ2VeFbzT2

[Suzanne Lepage @SuzanneLepage]

IQVIA Canada PRA subscribers – check out the May 2021 issue for 2 articles I co-authored:

(1) BC - Private and Public Payer Integration (with Brad Millson and Tommy Lan)

(2) Breaking Down the Facts About Private Drug Plan Costs (with @jfarago1)

[TELUS Health @TELUSHealth]

A great read from @BenCanMag that speaks to the need for specialty drug prior authorization – when prior authorization is delayed or declined, plan members' conditions can worsen. Learn more 👉 https://t.co/Og6oEinnfY

[TELUS Health @TELUSHealth]

The private-payer perspective matters when assessing the value of a medication – and pharmacoeconomic analysis can be a tool in the private-payer decision making process. Learn more from the @BenCanMag 2020 Face to Face Drug Plan Management Forum. 👉 https://t.co/DxGvL4mCvL

[Suzanne Lepage @SuzanneLepage]

Ensure you understand your prior authorization program to manage potential risks: https://t.co/Sh3w8wBeL5 via @BenCanMag

[Suzanne Lepage @SuzanneLepage]

How does your drug plan compare? Read the IMC Analysis of Private Drug Claim Cost Drivers (2016–2019) https://t.co/zN9XcuqPol

[Susan Landers, MD @susanlandersmd]

Such a wise statement. #BidenHarris2020 #pandemic